Role of substance P in the regulation of glucose metabolism via insulin signaling-associated pathways.
Substance P (SP), encoded by the tachykinin 1 (Tac1) gene, is the most potent tachykinin ligand for the high-affinity neurokinin-1 receptor (NK-1R). We previously reported that NK-1R-deficient mice show less weight gain and reduced circulating levels of leptin and insulin in response to a high-fat diet (HFD) and demonstrated the presence of functional NK-1R in isolated human preadipocytes. Here we assessed the effects of SP on weight gain in response to HFD and determined glucose metabolism in Tac1-deficient (Tac1(-/-)) mice. The effect of SP on the expression of molecules that may predispose to reduced glucose uptake was also determined in isolated human mesenteric, omental, and sc preadipocytes. We show that although weight accumulation in response to HFD was similar between Tac1(-/-) mice and wild-type littermates, Tac1(-/-) mice demonstrated lower glucose and leptin and increased adiponectin blood levels and showed improved responses to insulin challenge after HFD. SP stimulated phosphorylation of c-Jun N-terminal kinase, protein kinase C, mammalian target of rapamycin, and inhibitory serine insulin receptor substrate-1 phosphorylation in human preadipocytes in vitro. Preincubation of human mesenteric preadipocytes with the protein kinase C pseudosubstrate inhibitor reduced insulin receptor substrate 1 phosphorylation in response to SP. Lastly, SP also induced insulin receptor substrate-1 phosphorylation in mature human sc adipocytes. Our results demonstrate an important role for SP in adipose tissue responses and obesity-associated pathologies. These novel SP effects on molecules that enhance insulin resistance at the adipocyte level may reflect an important role for this peptide in the pathophysiology of type 2 diabetes.
Inflammatory Bowel Disease Center, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, 675 Charles E. Young Drive, Los Angeles, CA 90095, USA.
Iordanes
I
Karagiannides
Kyriaki
K
Bakirtzi
Efi
E
Kokkotou
Dimitris
D
Stavrakis
Kara Gross
KG
Margolis
Thomas
T
Thomou
Nino
N
Giorgadze
James L
JL
Kirkland
Charalabos
C
Pothoulakis
D017667:Adipocytes / Q000378:metabolism; D000818:Animals; D004041:Dietary Fats / Q000008:administration & dosage; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D051379:Mice; D018345:Mice, Knockout; D018040:Receptors, Neurokinin-1 / Q000502:physiology*; D015398:Signal Transduction; D013373:Substance P / Q000502:physiology*; D015320:Tachykinins / Q000172:deficiency / Q000502:physiology; D015430:Weight Gain
D004041:Dietary Fats; D007328:Insulin; D018040:Receptors, Neurokinin-1; D015320:Tachykinins; D013373:Substance P; D005947:Glucose